Axiom (Biotechnology)
$15.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Axiom (Biotechnology) is currently valued at $121.0M as of April 28, 2025. The company has raised a total of $30.0M in funding.
Capital Efficiency
With a capital efficiency ratio of 4.03x, Axiom (Biotechnology) has achieved a valuation that is 4.03 times the total capital raised. This metric indicates strong capital efficiency and effective deployment of investor funds.
Investment Perspective
Axiom (Biotechnology)'s valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Axiom (Biotechnology) Worth in 2025?
As of 2025, Axiom (Biotechnology) is valued at $121.0M, based on the company's Early Stage VC funding round in April 28, 2025. This valuation positions Axiom (Biotechnology) as one of the leading private companies in the sector.
Axiom (Biotechnology) Valuation History
Axiom (Biotechnology)'s funding history demonstrates steady growth and investor confidence.
How Axiom (Biotechnology) Valuation is Determined
Private company valuations like Axiom (Biotechnology)'s are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Axiom (Biotechnology) Valuation FAQs
Is Axiom (Biotechnology) profitable?
Axiom (Biotechnology) has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Axiom (Biotechnology)'s valuation compare to competitors?
Axiom (Biotechnology) is valued at $121.0M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Axiom (Biotechnology) IPO?
Axiom (Biotechnology) has not announced plans for an initial public offering. Until an IPO, investors can access Axiom (Biotechnology) shares through secondary market platforms.